Skip to main content

PMR

2023 Rheumatology Year in Review

Jan 12, 2024

Dr. Jack Cush reviews highlights, advances and hot topics in rheumatology from 2023 and the RheumNow website.  



2023 was a year of growth and new horizons while returning to operational and practice standards (in care and education) established before the pandemic.  



Below is

Read Article
ICYMI: When PMR Strikes Young, It Hits Hard https://t.co/rUuPnbcgCY https://t.co/AMpqGCJhIa
Dr. John Cush @RheumNow( View Tweet )
Jan 11, 2024

2023 Rheumatology Year in Review

Jan 10, 2024

Here is my top 10 list (in no particular order) of 2023 advances, game-changers, and developments that changed, or will soon change, rheumatologic practices.

Read Article
Full Read review of #PMR in Lancet: - Start @ 12·5–25mg prednisone qd - Remission in most but, relapses in 40–60% - Onset sudden; AM stiffness predominates; Shoulders>Pelvic ~50% have distal MSK Sxs - US: look for B/L sub-acromial/deltoid bursitis https://t.co/NwrbdMMdLU https://t.co/eRls0fLMJs
Dr. John Cush @RheumNow( View Tweet )
Dec 31, 2023
Best of 2023: PMR: glad or bad tidings? “Life was turned upside down overnight” – PMR patient. https://t.co/l7jZei5Kfm https://t.co/Ct3qlHd34P
Dr. John Cush @RheumNow( View Tweet )
Dec 29, 2023
When should we be starting therapy in GCA and PMR? The problem with having therapies that work is that you then have to figure out what to do with them. You cannot hide behind the ambiguity of therapeutic inadequacy. https://t.co/oRWTeH5Q9h https://t.co/BbswdffoKM
Dr. John Cush @RheumNow( View Tweet )
Dec 12, 2023
Full read BMJ ovverview of PMR - PMR Clinically recognized 1957 - Is it a uniquie vs overlap entity - Is there subclinical GCA in PMR? - Is PMR for PCPs? https://t.co/0BKGdt5Kxf https://t.co/sfAZoYyVan
Dr. John Cush @RheumNow( View Tweet )
Dec 11, 2023
2023 EULAR #PMR referral recommendations: 1 Suspected/Dx pts: consider Rheum eval 2 Do full Hx+PE+Labs before referral 3 Refer Severe Sx PMR to rapid access 4 Defer steroids til rapid Rheum eval 5 Rheum Dx PMR w? +steroid response can be Rx by PCP https://t.co/42bL8BL3QJ https://t.co/ffpKoKXZJM
Dr. John Cush @RheumNow( View Tweet )
Dec 05, 2023
Biologics as First-line Therapy for PMR and GCA? Dr. Eric Dein talks with Dr. Philip Seo, one of two panelists for the Great Debate: Should PMR and GCA Be Treated with Advanced Therapies at Disease Onset? https://t.co/eezZkBr8x7 https://t.co/D0dTSkjsNS https://t.co/nBlFyKNkHM
Dr. John Cush @RheumNow( View Tweet )
Dec 03, 2023

Is MTX Safe in the Elderly? (12.1.2023)

Dec 01, 2023

Dr. Jack Cush reviews this past week's news and journal reports from RheumNow.com. Good news is that nearly 99% of adult rheumatology positions matched! But the challenge is that 45% of pediatric fellowship programs and 39% of pediatric rheum slots were unfilled in the 2024 NRMP match.

Read Article

When should we be starting therapy in GCA and PMR?

Nov 28, 2023

The problem with having therapies that work is that you then have to figure out what to do with them. You cannot hide behind a shrug of the shoulders, or the ambiguity of therapeutic inadequacy. The question that follows the presence of a therapy is the question as to how to best use it.

GCA

Read Article
TM66 at #ACR23 60 yo M w/ worsening PMR symptoms (polyarthralgias, difficulty raising arms) & b/l vision loss PMH: PMR, central serous chorioretinopathy, HTN VS: 100.2 F, HR 108 Labs: - CRP 100 mg/dL, ESR 81 mm/h - UA: proteinuria (100 mg/dL) - ANA > 1:10,000, dsDNA > 300… https://t.co/T7Nov5vyoc https://t.co/3GuXVgh03Z
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Nov 14, 2023
👨‍⚖️ The Great Debate: should we use advanced therapies / biologics at disease onset in PMR & GCA? #ACR23 By Dr. Robert Spiera & Dr. Phil Seo @philseo #Vasculitis #PMR #GCA https://t.co/rkcUeEBLeZ
Mithu Maheswaranathan, MD ( View Tweet )
Nov 14, 2023
Clinical Year in Review at #ACR23 By @philseo (@jhrheumatology) Review some of the most impactful scientific studies in #Rheumatology in the past year! 🍕 https://t.co/ystEjzrU8u
Mithu Maheswaranathan, MD ( View Tweet )
Nov 14, 2023
International collaborative has discussed early referrals for PMR - this is what they’re recommending Better plans to get the right patients into rheumatologists is a big part of helping #MakeRheumForPMR ABST2395 #ACR23 @RheumNow https://t.co/Kea07IGxhG
David Liew @drdavidliew( View Tweet )
Nov 14, 2023
#irAE Baseline immune suppression does NOT protect against worsening synovitis flares when using check point inhibitors in Pts with established #inflammatory #arthritis #ACRbest #ACR23 @ACRheum @RheumNow abst1075 Data from #CanRIO database https://t.co/lOCf8Tbgta
Janet Pope ( View Tweet )
Nov 14, 2023
1-PJP prophylaxis or not in ANCA? 2-MTX single dose or split dose? 3-IL6 blocker early on in GCA/PMR? 4-SGLT2 in DM/Lupus nephritis? 5-Cervical cancer screening in Lupus? 6-TNF induced ILD? https://t.co/mzGXajmQqE @RheumNow , Daily recap #ACR23

Nouf Al hemmadi ( View Tweet )

Nov 14, 2023

#ACRbest Abstracts – Day 2

Nov 13, 2023

Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media.  Here are RheumNow's #ACRbest abstract reports from Monday, November 13, 2023 at #ACR23, covering The Great Debate, SGLPT2 inhibitors in SLE, the

Read Article
Still uncomfortable with IL-6i in GCA or PMR especially given the pt population and potential AE? Be on the look out for NEW biologics! Mavrilimumab Secukinumab and MORE! @RheumNow #ACR23 https://t.co/gdcDIcvffa
Robert B Chao, MD ( View Tweet )
Nov 13, 2023
More nuanced poll for #GreatDebate #ACR23 @RheumNow How should we use biologics for PMR/GCA?

Eric Dein ( View Tweet )

Nov 13, 2023
#ACR23 Great debate: should we use biologics at PMR/GCA onset? Dr Spiera (Cons) -Need to agree on clin important diff & flares -No evidence as disease modifying in GCA - No need for disease modifying in PMR -Most pts can be treated with steroid & rapid taper -Cost @RheumNow https://t.co/ptM8E7EQzF
Md Yuzaiful Md Yusof ( View Tweet )
Nov 13, 2023
Frailty in PMR @DrTrishHarkins >1/3 are frail or pre-frail. Frailty correlates with PROs - worse mood, pain, fatigue, and QoL. Abstr#1201 #ACR23 @RheumNow https://t.co/pH5yG4AscU https://t.co/QuHmOgpLbi
Richard Conway ( View Tweet )
Nov 13, 2023
The Great Debate #ACR23 - and it’s a cracker. Is early steroid-sparing therapy justified in GCA/PMR? I don’t know, but Rob Spiera and @philseo will battle it out to tell us. (and ably moderated by the always eloquent @SattuiSEMD) I’ll put some highlights here ⬇️🧵 @RheumNow https://t.co/ASpuglyENv
David Liew @drdavidliew( View Tweet )
Nov 13, 2023
Baseline vascular ultrasound predicts clinical outcomes @ 3 months. Subclinical GCA = relapse 37% vs 15%. Higher cumulative steroid dose. @sharoncowley01 @DrTrishHarkins Abstr#1565 #ACR23 @RheumNow https://t.co/b35CkFS0lz https://t.co/suBGR1ByDK
Richard Conway ( View Tweet )
Nov 13, 2023
So firstly the no case, and Rob Spiera takes up the case, dictated by the electronic coin toss. No-one disagrees that we need steroid-sparing options, or that IL-6Ri work in PMR and GCA. But it’s the strategy questions which remain in play: #ACR23 @RheumNow https://t.co/I2QDU7l6DE
David Liew @drdavidliew( View Tweet )
Nov 13, 2023